Tivozanib: Phase I/II started

Aveo began the open-label, French Phase Ib/II TiNivo trial to evaluate 1 and 1.5 mg oral tivozanib once daily for 21 days in combination with 240 mg IV Opdivo nivolumab every 2 weeks. The first part will test escalating doses of tivozanib plus Opdivo in 6-12 patients. The second part will further test the selected dose plus Opdivo in about 20 additional patients. ...